Accession NumberDB04904

Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
UNIINot Available
CAS numberNot Available

Intended for the treatment of cervical dysplasia associated with the human papillomavirus (HPV).

Structured Indications Not Available

Amolimogene was shown to be well tolerated in all patients and to promote the resolution of CIN 2/3 in women younger than 25 years.

Mechanism of action

Amolimogene particles are injected into the leg muscle and encounter cells known as antigen presenting cells, which play a pivotal role in activating the immune system. Once inside the dendritic cells, amolimogene dissolves and the genetic information that codes for parts of the HPV virus is released. The information is then processed, attaches to a protein and transported to the surface of the dendritic cell, attracting immune cells known as T cells. The T cells attach to the protein holding the information and begin to divide, creating many HPV targeted T cells. These cells migrate to the cervix where they encounter HPV expressing cells. Once inside the cervix, the T cells surround and eliminate the abnormal precancerous cells that cause cervical dysplasia. The result can be normal, healthy tissue.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Crum CP, Beach KJ, Hedley ML, Yuan L, Lee KR, Wright TC, Urban RG: Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol. J Infect Dis. 2004 Apr 15;189(8):1348-54. Epub 2004 Mar 30. [PubMed:15073670 ]
  2. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ: ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2004 Feb;103(2):317-26. [PubMed:14754702 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
2, 3CompletedTreatmentUterine Cervical Dysplasia1
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24